PharmD Info

A forum for Indian Pharmacy Professionals

New Drug Information's and other safety information, drug label changes, and Dose and Dosage Calculations, CDCSO,PvPI and FDA Safety Alerts and etc.
  • User avatar
#2032
Drug-eluting stents (DES) were designed to reduce in-stent neointimal proliferation, and thus,minimise in-stent restenosis (ISR), which is the major disadvantage of percutaneous coronary interventions with bare-metal stents (BMS). DES have revolutionised the treatment of coronary artery disease by reducing the rate of ISR from 20-40% with BMS to 6-8% with DES.

In recent years, however, concern has been raised regarding the long-term safety of DES and the risk of stent thrombosis (ST) and late restenosis due to neoatherosclerosis. This potential increased risk remains an area of uncertainty in the field of interventional cardiology.

DES consist of a standard metallic stent, a polymer coating, and an antiproliferative drug that is embedded within a durable or biodegradable (bioabsorbable) polymer and released over time. Although the common basic concept of DES remains constant, all DES are not made equal and each type may vary significantly with respect to deliverability, efficacy, and safety.

Image


Image
Similar Topics
Topics Statistics Last post
0 Replies 
552 Views
by Swathi Swaroopa B
WHO - Drug Disposal Guidelines
by Admin    - In: Treatment Guidelines
0 Replies 
22665 Views
by Admin
Various Approaches to Drug Discovery
by CPicklies    - In: Clinical Research
0 Replies 
2110 Views
by CPicklies
Drug profile Format- Example
by Admin    - In: Drug Information
0 Replies 
6863 Views
by Admin
Pocket Guide of Drug Interactions
by Admin    - In: Courses After Pharm D
0 Replies 
6658 Views
by Admin

Check Here to get the updates on oncology Phar[…]

When will the new (2022) batch start for fellowshi[…]

Vacancy for the post of Assistant Professor in the[…]

Clinical pharmacist vacancy in Fortis Hospital, Mu[…]

PharmD Info - Highlights